Evidence map›Paper›PMID 39639019›Full record

ArticleThe journal of physical chemistry. B2024

Furopyridine Derivatives as Potent Inhibitors of the Wild Type, L858R/T790M, and L858R/T790M/C797S EGFR.

Duangjai Todsaporn, Alexander Zubenko, Victor G Kartsev, Panupong Mahalapbutr, Athina Geronikaki, Samvel N Sirakanyan, Lyudmila N Divaeva, Victoria Chekrisheva, Ilkay Yildiz, Kiattawee Choowongkomon and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The journal of physical chemistry. B, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Innovative Amino-Functionalization of Pyrido[2,3-Pharmaceuticals (Basel, Switzerland) · 2025
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Duangjai TodsapornCenter of Excellence in Biocatalyst and Sustainable Biotechnology, Department of Biochemistry, Faculty of Science, Chulalongkorn University, Bangkok 10330, Thailand.
Alexander ZubenkoNorth-Caucasian Zonal Research Veterinary Institute, 346406 Novocherkassk, Russia.
Victor G KartsevInterBioScreen, 85355 Moscow, Russia.
Panupong MahalapbutrDepartment of Biochemistry, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand.ORCID 0000-0003-4389-334X
Athina GeronikakiDepartment of Pharmaceutical Chemistry, School of Health, Aristotle University of Thessaloniki, Thessaloniki 54124, Greece.
Samvel N SirakanyanThe Scientific Technological Center of Organic and Pharmaceutical Chemistry, Armenian Academy of Science, Institute of Fine Organic Chemistry of A.L. Mnjoyan, Avenue Azatutyan 26, Yerevan 0014, Armenia.
Lyudmila N DivaevaInstitute of Physical and Organic Chemistry, Southern Federal University, Pr. Stachki 194/2, 344090 Rostov-on-Don, Russia.
Victoria ChekrishevaNorth-Caucasian Zonal Research Veterinary Institute, 346406 Novocherkassk, Russia.
Ilkay YildizFaculty of Pharmacy, Department of Pharmaceutical Chemistry, Ankara University, Tandogan, Ankara 06100, Turkey.
Kiattawee ChoowongkomonDepartment of Biochemistry, Faculty of Science, Kasetsart University, Bangkok 10900, Thailand.ORCID 0000-0002-2421-7859
Thanyada RungrotmongkolCenter of Excellence in Biocatalyst and Sustainable Biotechnology, Department of Biochemistry, Faculty of Science, Chulalongkorn University, Bangkok 10330, Thailand.ORCID 0000-0002-7402-3235

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The treatment of patients with nonsmall cell lung cancer (NSCLC) using epidermal growth factor receptor (EGFR) inhibitors is complicated by drug-sensitive activating L858R/T790M and L858R/T790M/C797S mutations. To overcome drug resistance, a series of furopyridine (PD) compounds were virtually screened to identify potent EGFR inhibitors using molecular docking and molecular dynamics (MD) simulations based on the solvated interaction energy (SIE) method. Several PD compounds identified from virtual screening demonstrated the potential to suppress both wild-type and mutant forms of EGFR, with IC

Indexed as

ErbB ReceptorsMolecular Docking SimulationMolecular Dynamics SimulationMutationProtein Kinase InhibitorsPyridinesAntineoplastic AgentsCarcinoma, Non-Small-Cell LungCell Line, TumorFuransHumansLung NeoplasmsMolecular StructureAntineoplastic AgentsEGFR protein, humanErbB ReceptorsFuransProtein Kinase InhibitorsPyridines

Identifiers

PMID39639019
PMCPMC11664582

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.